S&P 500   4,543.86 (-0.13%)
DOW   35,662.62 (+0.17%)
QQQ   375.70 (-0.42%)
AAPL   149.55 (+0.05%)
MSFT   310.07 (-0.22%)
FB   324.07 (-5.21%)
GOOGL   2,757.00 (-2.84%)
TSLA   907.32 (+1.49%)
AMZN   3,383.30 (-1.51%)
NVDA   229.73 (+1.24%)
BABA   179.54 (+1.19%)
NIO   39.74 (-0.58%)
CGC   13.59 (-3.21%)
GE   104.43 (+1.24%)
AMD   120.11 (+0.65%)
MU   67.84 (-1.17%)
T   25.63 (-0.50%)
F   16.41 (-0.85%)
ACB   7.20 (-2.31%)
DIS   169.81 (-0.89%)
PFE   42.80 (-0.14%)
BA   215.12 (+0.36%)
AMC   36.75 (-6.35%)
S&P 500   4,543.86 (-0.13%)
DOW   35,662.62 (+0.17%)
QQQ   375.70 (-0.42%)
AAPL   149.55 (+0.05%)
MSFT   310.07 (-0.22%)
FB   324.07 (-5.21%)
GOOGL   2,757.00 (-2.84%)
TSLA   907.32 (+1.49%)
AMZN   3,383.30 (-1.51%)
NVDA   229.73 (+1.24%)
BABA   179.54 (+1.19%)
NIO   39.74 (-0.58%)
CGC   13.59 (-3.21%)
GE   104.43 (+1.24%)
AMD   120.11 (+0.65%)
MU   67.84 (-1.17%)
T   25.63 (-0.50%)
F   16.41 (-0.85%)
ACB   7.20 (-2.31%)
DIS   169.81 (-0.89%)
PFE   42.80 (-0.14%)
BA   215.12 (+0.36%)
AMC   36.75 (-6.35%)
S&P 500   4,543.86 (-0.13%)
DOW   35,662.62 (+0.17%)
QQQ   375.70 (-0.42%)
AAPL   149.55 (+0.05%)
MSFT   310.07 (-0.22%)
FB   324.07 (-5.21%)
GOOGL   2,757.00 (-2.84%)
TSLA   907.32 (+1.49%)
AMZN   3,383.30 (-1.51%)
NVDA   229.73 (+1.24%)
BABA   179.54 (+1.19%)
NIO   39.74 (-0.58%)
CGC   13.59 (-3.21%)
GE   104.43 (+1.24%)
AMD   120.11 (+0.65%)
MU   67.84 (-1.17%)
T   25.63 (-0.50%)
F   16.41 (-0.85%)
ACB   7.20 (-2.31%)
DIS   169.81 (-0.89%)
PFE   42.80 (-0.14%)
BA   215.12 (+0.36%)
AMC   36.75 (-6.35%)
S&P 500   4,543.86 (-0.13%)
DOW   35,662.62 (+0.17%)
QQQ   375.70 (-0.42%)
AAPL   149.55 (+0.05%)
MSFT   310.07 (-0.22%)
FB   324.07 (-5.21%)
GOOGL   2,757.00 (-2.84%)
TSLA   907.32 (+1.49%)
AMZN   3,383.30 (-1.51%)
NVDA   229.73 (+1.24%)
BABA   179.54 (+1.19%)
NIO   39.74 (-0.58%)
CGC   13.59 (-3.21%)
GE   104.43 (+1.24%)
AMD   120.11 (+0.65%)
MU   67.84 (-1.17%)
T   25.63 (-0.50%)
F   16.41 (-0.85%)
ACB   7.20 (-2.31%)
DIS   169.81 (-0.89%)
PFE   42.80 (-0.14%)
BA   215.12 (+0.36%)
AMC   36.75 (-6.35%)
NASDAQ:LIFE

aTyr Pharma Stock Forecast, Price & News

$8.51
-0.06 (-0.70 %)
(As of 10/22/2021 10:58 AM ET)
Add
Compare
Today's Range
$8.40
$8.56
50-Day Range
$4.52
$12.48
52-Week Range
$2.93
$13.10
Volume4,258 shs
Average Volume2.29 million shs
Market Capitalization$143.99 million
P/E RatioN/A
Dividend YieldN/A
Beta2
30 days | 90 days | 365 days | Advanced Chart
Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.


aTyr Pharma logo

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. Its product pipeline include ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1;DARS-1(3). The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
42
Year Founded
2005

Sales & Book Value

Annual Sales
$10.45 million
Book Value
$2.86 per share

Profitability

Net Income
$-16.22 million
Net Margins
-155.18%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$143.99 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

302nd out of 1,358 stocks

Biological Products, Except Diagnostic Industry

44th out of 196 stocks

Analyst Opinion: 4.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

Is aTyr Pharma a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" aTyr Pharma stock.
View analyst ratings for aTyr Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than aTyr Pharma?

Wall Street analysts have given aTyr Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but aTyr Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a decrease in short interest in September. As of September 30th, there was short interest totaling 1,560,000 shares, a decrease of 42.4% from the September 15th total of 2,710,000 shares. Based on an average daily volume of 5,320,000 shares, the days-to-cover ratio is presently 0.3 days.
View aTyr Pharma's Short Interest
.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for aTyr Pharma
.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its quarterly earnings data on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.13. aTyr Pharma had a negative net margin of 155.18% and a negative trailing twelve-month return on equity of 75.60%.
View aTyr Pharma's earnings history
.

How has aTyr Pharma's stock been impacted by COVID-19 (Coronavirus)?

aTyr Pharma's stock was trading at $3.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LIFE shares have increased by 182.8% and is now trading at $8.57.
View which stocks have been most impacted by COVID-19
.

When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?

Shares of aTyr Pharma reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for LIFE?

7 analysts have issued 1-year price objectives for aTyr Pharma's shares. Their forecasts range from $15.00 to $22.00. On average, they anticipate aTyr Pharma's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 121.7% from the stock's current price.
View analysts' price targets for aTyr Pharma
or view top-rated stocks among Wall Street analysts.

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the following people:
  • Sanjay S. Shukla, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Jill M. Broadfoot, Chief Financial Officer
  • Leslie Nangle, Vice President-Research
  • Andrew B. Cubitt, Vice President-External Scientific Alliances
  • Ashlee Dunston, Director-Investor Relations & Communications

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma CEO Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among aTyr Pharma's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $8.57.

How much money does aTyr Pharma make?

aTyr Pharma has a market capitalization of $145.00 million and generates $10.45 million in revenue each year. The biotechnology company earns $-16.22 million in net income (profit) each year or ($1.77) on an earnings per share basis.

How many employees does aTyr Pharma have?

aTyr Pharma employs 42 workers across the globe.

When was aTyr Pharma founded?

aTyr Pharma was founded in 2005.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is www.atyrpharma.com.

Where are aTyr Pharma's headquarters?

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 731-8389 or via email at [email protected].


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.